Vendor, Dallas, TX
Mark Cuban Cost Plus Drug Company, PBC
UEI N8P7MQ937WN7, CAGE 9VYL8
2 awards and $1,599,179 obligated between June 11, 2025 and May 8, 2026, 100% under full and open competition, against 1.5 offers on average where reported.
Industries
NAICS on the awards, by dollars.
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition After Exclusion of Sources | 2 |
| Small Business Set Aside - Total | 2 |
| Definitive Contract | 2 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| W911SR26CA011Definitive Contract, April 10, 2026, Full and Open Competition After Exclusion of Sources, 1 offers | W6QK ACC-APGDepartment of the Army | Mark Cuban Cost Plus Drug Company (Mccpdc) Intends to Generate a Chemistry, Manufacturing, and Controls (Cmc) Data Package Suitable for an FNAICS 541715, PSC AC12 | $1,393,259 |
| W911SR25CA006Definitive Contract, June 11, 2025, Full and Open Competition After Exclusion of Sources, 2 offers | W6QK ACC-APGDepartment of the Army | This Contract Is for Proof of Concept Production of Drug Substance Sterile Saline and Sterile Water Using Nonsterile Source Water Made UnderNAICS 541714, PSC AN13 | $205,920 |
- Places of performance
- Texas
- Product and service codes
- AC12 National Defense R&D Services; Department Of Defense - Military; Applied ResearchAN13 Health R&D Services; Health Care Services; Experimental Development
- Transactions
- 3 across 2 awards